{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T04:06:32Z","timestamp":1778126792660,"version":"3.51.4"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2020,5,1]]},"DOI":"10.1001\/jamaophthalmol.2020.0724","type":"journal-article","created":{"date-parts":[[2020,4,2]],"date-time":"2020-04-02T15:40:19Z","timestamp":1585842019000},"page":"560","source":"Crossref","is-referenced-by-count":12,"title":["Effect of Adjuvant Topical Dorzolamide-Timolol vs Placebo in Neovascular Age-Related Macular Degeneration"],"prefix":"10.1001","volume":"138","author":[{"given":"Jason","family":"Hsu","sequence":"first","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir N.","family":"Patel","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy D.","family":"Wolfe","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chirag P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Ophthalmic Consultants of Boston, Boston, Massachusetts"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Chen","sequence":"additional","affiliation":[{"name":"Retina Consultants of Houston, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas L.","family":"Jenkins","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turner D.","family":"Wibbelsman","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Obeid","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikel","family":"Mikhail","sequence":"additional","affiliation":[{"name":"Associated Retinal Consultants, William Beaumont Hospital, Royal Oak, Michigan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunir J.","family":"Garg","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen C.","family":"Ho","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allen","family":"Chiang","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc J.","family":"Spirn","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Vander","sequence":"additional","affiliation":[{"name":"The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"7","key":"eoi200022r1","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"issue":"14","key":"eoi200022r2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"issue":"12","key":"eoi200022r3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration.","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"20","key":"eoi200022r4","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration.","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"issue":"6","key":"eoi200022r5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.ophtha.2019.01.013","article-title":"Canadian treat-and-extend analysis trial with ranibizumab in patients with neovascular age-related macular disease: one-year results of the randomized canadian treat-and-extend analysis trial with ranibizumab study.","volume":"126","author":"Kertes","year":"2019","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200022r6","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","article-title":"Pharmacokinetics of intravitreal bevacizumab (Avastin).","volume":"114","author":"Bakri","year":"2007","journal-title":"Ophthalmology"},{"issue":"9","key":"eoi200022r7","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1097\/IAE.0b013e318158ea28","article-title":"Predicted biologic activity of intravitreal bevacizumab.","volume":"27","author":"Stewart","year":"2007","journal-title":"Retina"},{"issue":"2","key":"eoi200022r8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","article-title":"Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.","volume":"46","author":"Gaudreault","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"eoi200022r9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamaophthalmol.2016.0045","article-title":"Topical dorzolamide-timolol with intravitreous anti-vascular endothelial growth factor for neovascular age-related macular degeneration.","volume":"134","author":"Sridhar","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"eoi200022r10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s00417-008-0917-1","article-title":"Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide).","volume":"247","author":"Byeon","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"eoi200022r11","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/IAE.0000000000002293","article-title":"Efficacy of adjuvant topical dorzolamide-timolol in patients with neovascular age-related macular degeneration refractory to anti-vascular endothelial growth factor therapy.","volume":"39","author":"Lee","year":"2019","journal-title":"Retina"},{"issue":"4","key":"eoi200022r12","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1097\/IAE.0000000000002124","article-title":"Effect of intraocular pressure-lowering medications on neovascular age-related macular degeneration treatment outcomes in the Comparison of Age-related macular degeneration Treatment Trials.","volume":"39","author":"Rahimy","year":"2019","journal-title":"Retina"},{"issue":"12","key":"eoi200022r13","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/bjophthalmol-2014-305186","article-title":"Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy.","volume":"98","author":"Ritter","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"eoi200022r14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1016\/j.ophtha.2013.12.029","article-title":"Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.","volume":"121","author":"Simader","year":"2014","journal-title":"Ophthalmology"},{"issue":"5","key":"eoi200022r15","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ophtha.2018.11.025","article-title":"Tolerating subretinal fluid in neovascular age-related macular degeneration treated with ranibizumab using a treat-and-extend regimen: FLUID study 24-month results.","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"issue":"4","key":"eoi200022r16","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/j.ophtha.2015.12.002","article-title":"Macular morphology and visual acuity in the second year of the comparison of age-related macular degeneration treatments trials.","volume":"123","author":"Sharma","year":"2016","journal-title":"Ophthalmology"},{"issue":"6","key":"eoi200022r17","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD.","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye (Lond)"},{"issue":"2","key":"eoi200022r18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0161-6420(99)00044-5","article-title":"Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects.","volume":"107","author":"Brubaker","year":"2000","journal-title":"Ophthalmology"},{"issue":"1","key":"eoi200022r19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1167\/iovs.10-5536","article-title":"Role of the adrenergic system in a mouse model of oxygen-induced retinopathy: antiangiogenic effects of beta-adrenoreceptor blockade.","volume":"52","author":"Ristori","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"eoi200022r20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1111\/jnc.2011.119.issue-6","article-title":"Antiangiogenic effects of \u00df2-adrenergic receptor blockade in a mouse model of oxygen-induced retinopathy.","volume":"119","author":"Martini","year":"2011","journal-title":"J Neurochem"},{"key":"eoi200022r21","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.preteyeres.2014.06.001","article-title":"The \u00df-adrenergic system as a possible new target for pharmacologic treatment of neovascular retinal diseases.","volume":"42","author":"Casini","year":"2014","journal-title":"Prog Retin Eye Res"},{"issue":"3","key":"eoi200022r22","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1001\/jamaophthalmol.2013.1476","article-title":"Attenuation of choroidal neovascularization by \u00df(2)-adrenoreceptor antagonism.","volume":"131","author":"Lavine","year":"2013","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"eoi200022r23","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1097\/IAE.0b013e3182695ba0","article-title":"Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.","volume":"33","author":"Montero","year":"2013","journal-title":"Retina"},{"issue":"1","key":"eoi200022r24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1097\/IAE.0000000000001226","article-title":"Systemic beta-blockers in neovascular age-related macular degeneration.","volume":"37","author":"Traband","year":"2017","journal-title":"Retina"},{"issue":"5","key":"eoi200022r25","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ajo.2005.12.030","article-title":"Topical dorzolamide for the treatment of cystoid macular edema in patients with retinitis pigmentosa.","volume":"141","author":"Grover","year":"2006","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi200022r26","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/IAE.0b013e3182215ae9","article-title":"Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.","volume":"32","author":"Genead","year":"2012","journal-title":"Retina"},{"issue":"2","key":"eoi200022r27","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1001\/archophthalmol.2009.398","article-title":"Efficacy of sustained topical dorzolamide therapy for cystic macular lesions in patients with X-linked retinoschisis.","volume":"128","author":"Genead","year":"2010","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"eoi200022r28","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/S0161-6420(02)01157-0","article-title":"Acetazolamide for central serous retinopathy.","volume":"109","author":"Pikkel","year":"2002","journal-title":"Ophthalmology"},{"issue":"2","key":"eoi200022r29","first-page":"142","article-title":"Membrane-bound carbonic anhydrase activity in the rat corneal endothelium and retina.","volume":"40","author":"Terashima","year":"1996","journal-title":"Jpn J Ophthalmol"},{"issue":"6","key":"eoi200022r30","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1085\/jgp.200810169","article-title":"CO2-induced ion and fluid transport in human retinal pigment epithelium.","volume":"133","author":"Adijanto","year":"2009","journal-title":"J Gen Physiol"},{"issue":"4","key":"eoi200022r31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S0002-9394(01)01158-8","article-title":"Effect of dorzolamide timolol combination versus timolol 0.5% on ocular bloodflow in patients with primary open-angle glaucoma.","volume":"132","author":"Harris","year":"2001","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"eoi200022r32","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1136\/bjo.87.6.753","article-title":"The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration.","volume":"87","author":"Harris","year":"2003","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"eoi200022r33","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1167\/iovs.07-0508","article-title":"Dorzolamide increases retinal oxygen tension after branch retinal vein occlusion.","volume":"49","author":"Noergaard","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2763872\/jamaophthalmology_hsu_2020_oi_200022.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T02:42:22Z","timestamp":1589510542000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2763872"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.0724","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}